Drugs / recombinant-hCG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT02145247 Comparator | May 2014 → Feb 2017 | polycystic ovary syndrome | University of California, San Diego | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant-hCG | “recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.” NCT02145247 ↗ |
| Known as | hCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02145247 ↗ |
| Known as | r-hCG | “recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.” NCT02145247 ↗ |
| Route | Intravenous | “administered intravenously” NCT02145247 ↗ |